May M E, Mancusi V J, Aftring R P, Buse M G
Am J Physiol. 1980 Sep;239(3):E215-22. doi: 10.1152/ajpendo.1980.239.3.E215.
Oxidative decarboxylation is the first irreversible step in the degradation of leucine. The effect of streptozotocin diabetes on this reaction was studied in cell-free rat liver preparations, using [1-14C]alpha-ketoisocaproate as substrate. Diabetes increased the branched-chain ketoacid dehydrogenase (BCKD) activity (per g liver or per mg protein) of homogenates, but the ratios of homogenate BCKD activity to other mitochondrial markers remained unchanged. A cytosolic branched-chain ketoacid decarboxylase activity (15-22% of homogenate activity), which did not require NAD, CoA, or NADP, was also increased in diabetics. Insulin treatment of diabetics normalized enzyme activity in all fractions. The apparent Km of BCKD in homogenates was 43-45 microM; diabetes increased the apparent Vmax from 165 nmol x min-1 x g tissue-1 to 260 nmol x min-1 x g-1. In contrast, the Km for cytosolic alpha-ketoisocaproate decarboxylation was 270 microM in controls, and diabetes resulted in both a lower Km (210 microM) and a higher Vmax. Adrenalectomy did not affect activity in homogenates from controls, but partially reversed the diabetes-associated increase. Glucagon pretreatment of controls did not affect activity. In summary, distinct mitochondrial and cytosolic enzymes decarboxylate alpha-ketoisocaproate in liver. The increased hepatic capacity of diabetic rats to degrade the carbon skeleton of leucine is attributed mainly to a relative increase in mitochondrial mass.
氧化脱羧作用是亮氨酸降解过程中的第一个不可逆步骤。本研究以[1-14C]α-酮异己酸为底物,在无细胞大鼠肝脏制剂中研究了链脲佐菌素诱导的糖尿病对该反应的影响。糖尿病使匀浆中支链酮酸脱氢酶(BCKD)的活性(每克肝脏或每毫克蛋白质)增加,但匀浆BCKD活性与其他线粒体标志物的比值保持不变。糖尿病大鼠中还存在一种胞质支链酮酸脱羧酶活性(占匀浆活性的15-22%),该活性不需要NAD、辅酶A或NADP,也有所增加。对糖尿病大鼠进行胰岛素治疗可使所有组分中的酶活性恢复正常。匀浆中BCKD的表观Km为43-45微摩尔;糖尿病使表观Vmax从165纳摩尔·分钟-1·克组织-1增加到260纳摩尔·分钟-1·克-1。相比之下,对照组中胞质α-酮异己酸脱羧作用的Km为270微摩尔,糖尿病导致Km降低(210微摩尔)且Vmax升高。肾上腺切除术对对照组匀浆中的活性没有影响,但部分逆转了糖尿病相关的活性增加。对对照组进行胰高血糖素预处理不影响活性。总之,肝脏中存在不同的线粒体和胞质酶可使α-酮异己酸脱羧。糖尿病大鼠肝脏降解亮氨酸碳骨架的能力增强主要归因于线粒体质量的相对增加。